STARPHARMA HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.135 AUD | 0.00% |
|
+3.85% | -20.59% |
| Apr. 08 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
| Mar. 18 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 431.7 | 505.5 | 419.1 | 607.1 | 302.2 | 127.3 |
| Enterprise Value (EV) 1 | 380.4 | 464.3 | 390.7 | 547.8 | 260.5 | 100.3 |
| P/E ratio | -38.8 x | -34 x | -28.1 x | -29.9 x | -18.5 x | -7.75 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 87.1 x | 186 x | 63.9 x | 174 x | 58.6 x | 30.2 x |
| EV / Revenue | 76.7 x | 171 x | 59.6 x | 157 x | 50.5 x | 23.8 x |
| EV / EBITDA | -38.1 x | -33.3 x | -26.1 x | -28.2 x | -16.5 x | -6.52 x |
| EV / FCF | -64.5 x | -98.5 x | -71 x | -69.4 x | -31.4 x | -11.1 x |
| FCF Yield | -1.55% | -1.02% | -1.41% | -1.44% | -3.18% | -8.98% |
| Price to Book | 8.1 x | 11.9 x | 13.4 x | 9.74 x | 6.25 x | 3.66 x |
| Nbr of stocks (in thousands) | 370,545 | 371,694 | 372,563 | 406,078 | 408,443 | 410,493 |
| Reference price 2 | 1.165 | 1.360 | 1.125 | 1.495 | 0.7400 | 0.3100 |
| Announcement Date | 8/21/18 | 8/28/19 | 8/26/20 | 8/25/21 | 8/24/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.957 | 2.72 | 6.556 | 3.487 | 5.162 | 4.208 |
| EBITDA 1 | -9.974 | -13.96 | -14.96 | -19.43 | -15.8 | -15.38 |
| EBIT 1 | -10.28 | -14.25 | -15.24 | -19.73 | -16.15 | -15.77 |
| Operating Margin | -207.48% | -524.04% | -232.41% | -565.87% | -312.94% | -374.83% |
| Earnings before Tax (EBT) 1 | -10.28 | -14.25 | -14.68 | -19.73 | -16.15 | -15.64 |
| Net income 1 | -10.28 | -14.25 | -14.68 | -19.73 | -16.15 | -15.64 |
| Net margin | -207.48% | -524.04% | -223.89% | -565.87% | -312.94% | -371.63% |
| EPS 2 | -0.0300 | -0.0400 | -0.0400 | -0.0500 | -0.0400 | -0.0400 |
| Free Cash Flow 1 | -5.902 | -4.715 | -5.503 | -7.896 | -8.293 | -9.013 |
| FCF margin | -119.07% | -173.34% | -83.94% | -226.43% | -160.66% | -214.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/21/18 | 8/28/19 | 8/26/20 | 8/25/21 | 8/24/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2023 S1 |
|---|---|---|---|---|
| Net sales 1 | 5.671 | - | - | 1.607 |
| EBITDA | - | -9.124 | - | - |
| EBIT 1 | - | -9.579 | - | -8.277 |
| Operating Margin | - | - | - | -515.06% |
| Earnings before Tax (EBT) | - | -8.815 | -10.43 | - |
| Net income 1 | - | -8.815 | -10.43 | -8.277 |
| Net margin | - | - | - | -515.06% |
| EPS | -0.0158 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/23/20 | 8/26/20 | 2/24/21 | 2/27/23 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 51.3 | 41.2 | 28.5 | 59.3 | 41.7 | 26.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.9 | -4.71 | -5.5 | -7.9 | -8.29 | -9.01 |
| ROE (net income / shareholders' equity) | -18% | -29.8% | -39.8% | -42.2% | -29.2% | -37.6% |
| ROA (Net income/ Total Assets) | -10.3% | -16.6% | -21.7% | -22% | -14.5% | -16.7% |
| Assets 1 | 100.1 | 85.9 | 67.77 | 89.85 | 111.5 | 93.8 |
| Book Value Per Share 2 | 0.1400 | 0.1100 | 0.0800 | 0.1500 | 0.1200 | 0.0800 |
| Cash Flow per Share 2 | 0.1400 | 0.1100 | 0.0800 | 0.1500 | 0.1200 | 0.0900 |
| Capex 1 | 0.36 | 0.31 | 0.13 | 0.25 | 0.84 | 0.62 |
| Capex / Sales | 7.24% | 11.54% | 1.91% | 7.05% | 16.21% | 14.76% |
| Announcement Date | 8/21/18 | 8/28/19 | 8/26/20 | 8/25/21 | 8/24/22 | 8/23/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 36.28M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SPL Stock
- Financials Starpharma Holdings Limited
